Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperimmune caprine serum against HIV lysate is a biologic product derived from the blood of goats that have been immunized with detergent-inactivated HIV viral lysate. The resulting serum contains high levels of polyclonal anti-HIV antibodies (immunoglobulins) and various small molecular weight proteins, including cytokines such as IL-4 and IL-10, proopiomelanocortin, arginine vasopressin, β-endorphin, corticotropin-releasing factor (CRH), α-2 macroglobulin (α-2M), and lipoprotein-related peptide-1 complex[3][2]. The primary mechanism is believed to be immunomodulation through modulation of cytokine activity—particularly increasing or modulating IL-10—and direct neutralization or opsonization of HIV particles via the polyclonal antibodies[1][3]. It has been investigated for use in autoimmune diseases such as diffuse cutaneous systemic sclerosis (dcSSc), multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy[2][3]. Its precise mechanism remains incompletely understood but includes both immune modulation and possible sodium channel opening effects in neural tissues[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperimmune caprine serum against hiv lysate.